Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05552326
Other study ID # ISIS 678354-CS6
Secondary ID 2022-501420-20
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 31, 2022
Est. completion date July 2025

Study information

Verified date May 2024
Source Ionis Pharmaceuticals, Inc.
Contact Ionis Pharmaceuticals
Phone 844-366-0213
Email ionisSHTG2study@clinicaltrialmedia.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.


Description:

This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study in up to approximately 390 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation in the study will be approximately 78 weeks, which includes an up to 12-week screening period, a 53-week treatment period, and a 13-week post-treatment evaluation period or transition to open-label extension (OLE) study with up to 1-year treatment. The Screening Period was extended with no impact to overall study timelines. Endpoints added to provide assessment on the pancreatitis rate after olezarsen reaches steady state levels.


Recruitment information / eligibility

Status Recruiting
Enrollment 390
Est. completion date July 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Fasting TG = 500 mg/dL (5.65 mmol/L) at Screening and Qualification 2. Participants must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to screening to minimize changes in these medications during the study. 3. Participants must be willing to comply with diet and lifestyle recommendations as able. Exclusion Criteria: 1. Hemoglobin A1c (HbA1c) = 9.5% at Screening 2. Alanine aminotransferase or aspartate aminotransferase > 3.0 × upper limit of normal 3. Total bilirubin > 1.5 ULN unless due to Gilbert's syndrome 4. Estimated GFR < 30 mL/min/1.73 m^2

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Olezarsen
Olezarsen will be administered by SC injection.
Placebo
Olezarsen-matching placebo will be administered by SC injection.

Locations

Country Name City State
Argentina Centro Médico Dra. Laura Maffei Buenos Aires
Argentina Glenny Corp SA Buenos Aires
Argentina CIPREC - Centro de Investigación y Prevención Cardiovascular Ciudad Autónoma de Buenos Aires
Argentina Fundacion Favaloro Ciudad Autónoma de Buenos Aires
Argentina Instituto Médico DAMIC Córdoba
Argentina Instituto de Cardiología Corrientes Corrientes
Argentina Centro Medico San Luis San Luis
Argentina Clínica FUSAVIM Privada Villa María
Belgium AZ Sint-Jan Brugge Brugge
Belgium Hôpital Erasme Brussels
Belgium Virga Jessa Hospital Hasselt
Belgium UZ Leuven Leuven
Brazil NUPEC - Nucleo de Pesquisa Clinica Belo Horizonte
Brazil Núcleo de Pesquisa Clínica Curitiba
Brazil Hospital Universitario Walter Cantidio - UFC Fortaleza
Brazil Nucleo de Pesquisa em Cirurgia Vascular Porto Alegre
Brazil IBPClin Pesquisa Clinica Rio De Janeiro
Brazil Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - FMUSP Sao Paulo
Brazil CPQuali Pesquisa Clinica São Paulo
Brazil i9 Pesquisas Clínicas/Loema - Instituto de Pesquisas Clínica & Consultores São Paulo
Brazil Instituto do Coração - HCFMUSP São Paulo
Bulgaria Medical Center Diamedical EOOD Dimitrovgrad
Bulgaria MHAT Haskovo AD Haskovo
Bulgaria MHAT Pazardzhik AD Pazardzhik
Bulgaria UMHAT - Kaspela EOOD Plovdiv
Bulgaria University Multiprofile Hospital for Active Treatment Pulmed OOD Plovdiv
Bulgaria UMHAT Kanev AD Ruse
Bulgaria MHAT Sliven to MMA Sofia Sliven
Bulgaria Medical Center Smolyan Clinical Research OOD Smolyan
Bulgaria Acibadem City Clinic Tokuda University Hospital Sofia
Bulgaria Medical Center for Specialized Medical Help in Cardiovascular Diseases OOD Sofia
Bulgaria Medical Centre Synexus Sofia EOOD Sofia
Bulgaria Medico Dental Center ISUL Tsaritsa Yoanna EOOD Sofia
Bulgaria Medical Center Zara - Med Stara Zagora
Bulgaria DCC Equita Varna
Bulgaria Specialized Hospital for Active Treatment of Cardiology Varna
Bulgaria Medical Centre "Nevromedics" EOOD Veliko Tarnovo
Canada Aggarwal and Associates Ltd. Brampton Ontario
Canada Joanne F. Liutkus Medicine Professional Corporation Cambridge Ontario
Canada NL Health Services Saint John's Newfoundland and Labrador
Canada Bluewater Clinical Research Group Sarnia Ontario
Canada Unite de Recherche Clinique St Jerome Quebec
Canada Toronto General Hospital Toronto Ontario
Czechia CTC Hodonin s.r.o. Hodonín
Czechia KardioBusak s.r.o. Louny
Czechia Fakultni nemocnice v Motole Prague
Czechia Endokrinologie Cerny Most s.r.o. Praha
Czechia Diabetologická a endokrinologická ambulance Milan Kvapil Príbram
Czechia AeskuLab k.s Teplice
France Hopital de Hautepierre Strasbourg
France ELSAN - Polyclinique Vauban Valenciennes
France GHM les Portes du Sud Vénissieux
Greece University General Hospital of Alexandroupoli Alexandroupoli
Greece AHEPA Building of Evaggelismos Athens
Greece Hygeia Hospital Athens
Greece University General Hospital ATTIKON Athens
Greece AHEPA University General Hospital of Thessaloniki Thessaloníki
Hungary Lausmed Kft. Baja
Hungary DRC Gyogyszervizsgalo Kozpont Kft Balatonfured
Hungary Clinexpert Kft. Budapest
Hungary Obudai Egeszsegugyi Centrum Budapest
Hungary Pharma4 Trial Kft. Gyöngyös
Hungary Somogy Varmegyei Kaposi Mor Oktato Korhaz Diabetologiai szakrendeles Kaposvár
India Sri Jayadeva Institute of Cardiovascular Sciences and Research Bengaluru
India Sir Ganga Ram Hospital Delhi
India Eternal Hospital Jaipur
India B. M. Birla Heart Research Centre A Unit of the Calcutta Medical Research Institute Kolkata West Bengal
India IPGMER Kolkata
India Vinaya Hospital and Research Centre (A Unit of Karnataka Institute of Medical Sciences) Mangaluru
India Bhatia Hospital Mumbai
India KEM Hospital Mumbai
India Manipal Hospital Mysore Mysore
India Max Super Specialty Hospital New Delhi Delhi
Italy Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Bergamo
Italy AORN S. Anna e S. Sebastiano UOC FARMACIA Caserta
Italy Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant'Anna Cona
Italy Fondazione I.R.C.C.S. Policlinico "San Matteo" c/o C.U.R.M. Pavia
Lithuania Pirmoji viltis Šiauliai
Lithuania Klinikiniai sprendimai Kaunas
Lithuania Saules seimons medicinos centras Kaunas
Lithuania Clinic of Cardiology and Rehabilitation Klaipeda
Lithuania Republican Panevezys Hospital Panevežys
Malaysia Sultanah Bahiyah Hospital Alor Setar Kedah
Malaysia Pulau Pinang Hospital George Town Pulau Pinang
Malaysia University Malaya Medical Centre (UMMC) Kuala Lumpur
Malaysia Hospital Taiping Taiping Perak
Mexico Centro de Investigación Cardiométabolica de Aguascalientes S.A. de C.V. Aguascalientes
Mexico Cientia Investigacion Clinica Sc Chihuahua
Mexico Medical Care and Research S.A de C.V. Mérida Yucatan
Mexico Clinstile, S.A. de C.V. Mexico City
Mexico Clinical Research Institute S.C. Tlanepantla
Netherlands Vumc Amsterdam Medical Center Amsterdam
Netherlands Gelre Ziekenhuizen Apeldoorn Apeldoorn
Netherlands Reinier de Graaf Ziekenhuis Delft
Netherlands Het Van Weel Bethesda ziekenhuis Dirksland
Netherlands Albert Schweitzer Ziekenhuis Dordrecht
Netherlands Bethesda Diabetes Research Center Hoogeveen
Netherlands Canisius-Wilhelmina Ziekenhuis (CWZ) Nijmegen
Poland UCK, I Klinika Kardiologii Gdansk
Poland Biokinetica Józefów
Poland Centrum Medyczne Pratia Katowice
Poland Centra Medyczne Medyceusz Lódz
Poland Clinical Best Solutions Lublin
Poland Etg Lublin Lublin
Poland Centrum Zdrowia Metabolicznego Poznan
Poland Centrum Medycnze AMED Warsaw
Poland Clinical Best Solutions Sp. Z.o.o Spolka Komandytowa Warsaw
Poland Narodowy Instytut Kardiologii im. S. Wyszynskiego - PIB Warszawa
Poland ETG Zamosc / Pro Life Medica Sp. z o.o. Zamosc
Portugal Hospital CUF Tejo Lisboa
Portugal Centro Hospitalar de Entre Douro e Vouga Santa Maria Da Feira
Romania Cabinet Medical Individual SC DIANA BARBONTA SRL Alba
Romania Cardioplus Center SRL Baia Mare
Romania Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed S.R.L Brasov
Romania Centrul Medical Medicover Victoria Bucuresti
Romania S.C. SAL MED S.R.L., Cardiologie Pitesti
Romania Cardio Med SRL Târgu-Mures
Romania S.C. Mediab Srl Târgu-Mures
Slovakia Alian s.r.o. Bardejov
Slovakia Ambulancia diabetologicka a poruch latkovej premeny a vyzivy Bratislava
Slovakia Interna a diabetologicka ambulancia - IN-DIA s.r.o. Lucenec
Slovakia Diab sro Rožnava
Slovakia Interna SK, s.r.o. Svidník
Slovakia Areteus s.r.o Trebišov
Spain Hospital Germans Trias i Pujol Badalona
Spain Hospital Vall d'Hebron Barcelona
Spain Hospital Comarcal Infanta Elena Huelva
Spain Hospital Universitario de Jaen Jaén
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Regional de Malaga Malaga
Spain Unidad de Ensayos Clinicos Malaga
Spain Hospital Provincial de Conxo Santiago De Compostela
Spain Hospital Universitario Virgen Macarena Sevilla
Spain Hospital Clinico Universitario de Valencia Valencia
Spain Hospital Universitario Miguel Servet Zaragoza
Sweden Acardo MedSite Solna
Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) Kaohsiung
Taiwan Mackay Memorial Hospital New Taipei City
Taiwan Taichung Veterans General Hospital Taichung City
Taiwan National Cheng Kung University Hospital Tainan
Taiwan Shin Kong Wu Ho-Su Memorial Hospital Taipei City
Taiwan Chang Gung Medical Foundation - Linkou Branch Taoyuan
United States Emory University Atlanta Georgia
United States Maryland Cardiovascular Specialists Baltimore Maryland
United States University of Maryland School of Medicine Baltimore Maryland
United States Alabama Clinical Therapeutics, LLC Alabaster Birmingham Alabama
United States Central Research Associates, Inc. Birmingham Alabama
United States Grace Research, LLC Bossier City Louisiana
United States Massachusetts General Hospital Boston Massachusetts
United States St. Vincent Medical Group Carmel Indiana
United States Medical University of South Carolina (MUSC) Charleston South Carolina
United States The Ohio State University (OSU) Columbus Ohio
United States Accel Research Sites DeLand Florida
United States Accel Clinical Research Eatonton Georgia
United States Onyx Clinical Research Flint Michigan
United States Texas Health Family Care Fort Worth Texas
United States Northeast Georgia Medical Center Gainesville Georgia
United States Finlay Medical Research Greenacres City Florida
United States Clinical Trial Network Houston Texas
United States Juno Research Houston Texas
United States Juno Research Houston Texas
United States Pioneer Research Solutions, Inc Houston Texas
United States Vilo Research Group Houston Texas
United States The Jackson Clinic Jackson Tennessee
United States University of Florida Jacksonville Jacksonville Florida
United States University of Kansas Medical Center (KUMC) Kansas City Kansas
United States Clinical Investigation Specialists Inc. Kenosha Wisconsin
United States Sante Clinical Research, LLC Kerrville Texas
United States FMC Science Lampasas Texas
United States Clinical Trials of America, LLC Lenoir North Carolina
United States The Research Group of Lexington, LLC Lexington Kentucky
United States Main Street Physicians Care Waterway Little River South Carolina
United States NRC Research Institute Los Angeles California
United States Louisville Metabolic and Atherosclerosis Research Center (L-MARC) Louisville Kentucky
United States University of Louisville Louisville Kentucky
United States Meridien Research Maitland Florida
United States SV Research LLC Marion Ohio
United States DCT - McAllen Primary Care, LLC McAllen Texas
United States McAllen Primary Care, LLC McAllen Texas
United States Texas Institute of Cardiology McKinney Texas
United States SMS Clinical Research, LLC Mesquite Texas
United States Southern Endocrinology Associates Mesquite Texas
United States Columbus Clinical Services Miami Florida
United States NYU Langone Hospital - Long Island Mineola New York
United States Clinical Trials of America LA, LLC Monroe Louisiana
United States Diabetes and Endocrinology Consultants, P.C. Morehead City North Carolina
United States Randomize Now Newnan Georgia
United States Harmony Clinical Research, Inc North Miami Beach Florida
United States Permian Research Foundation Odessa Texas
United States Orchard Park Family Practice Orchard Park New York
United States Aspen Clinical Research Orem Utah
United States Combined Research Orlando Phase I-IV Orlando Florida
United States Onyx Clinical Research Peoria Arizona
United States University of Pennsylvania Philadelphia Pennsylvania
United States Monument Health Clinical Research Rapid City South Dakota
United States Onyx Clinical Research Rochester Hills Michigan
United States Ogden Clinic Grandview Roy Utah
United States OnSite Clinical Solutions, LLC Salisbury North Carolina
United States Diabetes & Glandular Disease Clinic, P.A. San Antonio Texas
United States Stern Cardiovascular Southaven Mississippi
United States 3Sync Research Sunrise Florida
United States JSV Clinical Research Study, Inc. Tampa Florida
United States R & B Medical Center LLC Tampa Florida
United States Oklahoma Heart Institute Tulsa Oklahoma
United States Tranquil Research Webster Texas
United States Metabolic Research Institute West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Ionis Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Belgium,  Brazil,  Bulgaria,  Canada,  Czechia,  France,  Greece,  Hungary,  India,  Italy,  Lithuania,  Malaysia,  Mexico,  Netherlands,  Poland,  Portugal,  Romania,  Slovakia,  Spain,  Sweden,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change from Baseline in Fasting TG at 6 Months (Average of Weeks 25 and 27) Compared to Placebo Baseline and Month 6
Secondary Percent Change from Baseline in Fasting TG at 12 Months (Average of Weeks 51 and 53) Compared to Placebo Baseline and Month 12
Secondary Proportion of Participants Who Achieve Fasting TG Less Than (<) 500 milligrams per deciliter (mg/dL) (5.7 millimoles per liter [mmol/L]) at 6 and 12 Months Compared to Placebo Month 6 and Month 12
Secondary Proportion of Participants Who Achieve Fasting TG < 880 mg/dL (10 mmol/L) at 6 and 12 Months Compared to Placebo in the Subgroup of Participants with Baseline TG = 880 mg/dL Month 6 and Month 12
Secondary Percentage of Participants Achieving Fasting TG < 1000 mg/dL in Participants with Baseline TG = 1000 mg Month 6 and Month 12
Secondary Percent Change from Baseline in Fasting Apolipoprotein C-III (ApoC-III) at 6 and 12 Months Compared to Placebo Baseline, Month 6 and Month 12
Secondary Percent Change from Baseline in Fasting Very Low-Density Lipoprotein Cholesterol (VLDL-C) at 6 and 12 Months Compared to Placebo Baseline, Month 6 and 12
Secondary Percent Change from Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at 6 and 12 Months Compared to Placebo Baseline, Month 6 and 12
Secondary Percent Change from Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) at 6 and 12 Months Compared to Placebo Baseline, Month 6 and 12
Secondary Adjudicated Acute Pancreatitis Event Rate During the Treatment Period Compared to Placebo, in Participants with = 2 Events of Adjudicated Acute Pancreatitis in 5 Years Prior to Enrollment Week 1 through Week 53
Secondary Acute Pancreatitis Event Rate from Week 13 to Week 53 Compared to Placebo, in Participants with = 2 Events of Adjudicated Acute Pancreatitis in 5 Years Prior to Enrollment Week 13 through Week 53
Secondary Adjudicated Acute Pancreatitis Event Rate During the Treatment Period Compared to Placebo Week 1 through Week 53
Secondary Adjudicated Acute Pancreatitis Event Rate from Week 13 to Week 53 Compared to Placebo Week 13 through Week 53
See also
  Status Clinical Trial Phase
Completed NCT01208961 - Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation Phase 2
Completed NCT04541186 - Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia Phase 2
Active, not recruiting NCT05079919 - A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia Phase 3
Completed NCT02189252 - An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis Phase 1
Active, not recruiting NCT01229566 - Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia Phase 3
Completed NCT03001817 - Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function Phase 3
Completed NCT03011450 - Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment Phase 3
Completed NCT05355402 - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia Phase 2
Completed NCT04720534 - Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia Phase 2
Recruiting NCT06347003 - Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Phase 3
Recruiting NCT06347016 - Study of Plozasiran in Adults With Severe Hypertriglyceridemia Phase 3
Withdrawn NCT04662528 - Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL Phase 3
Recruiting NCT05852431 - To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia Phase 3
Completed NCT01242527 - Epanova® for Lowering Very High Triglycerides Phase 2/Phase 3
Completed NCT02944383 - A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia Phase 2
Recruiting NCT05681351 - A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) Phase 3
Withdrawn NCT01997268 - The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL) Phase 3